Jaundice, NeonatalLEDlightT2NCT03569254
Effectiveness, Safety and Perceptions With the Use of One LED Blanket Device in the Ambulatory Treatment of Jaundice
A study testing Neomedlight Phototherapy Blanket and Ohmeda-Fiber Optic Phototherapy Blanket in people with Jaundice, Neonatal and Phototherapy, run by Nathalie Charpak at 1 site in Colombia.
Trial summary
Objective: to evaluate the effectiveness, safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy to which a LED light mesh has been incorporated(a blanket), comparing it with the Ohmeda BiliBlanket Plus®. Read more about this study
- Who is it for?
- Ages Up to 1 month
- Conditions the study is for
- Jaundice, Neonatal, Phototherapy
- What is being tested?
- Neomedlight Phototherapy Blanket and Ohmeda-Fiber Optic Phototherapy Blanket
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 1 siteColombia
- Study dates
- 1 Mar 2016to 5 Oct 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 1 month
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Low Risk Hyperbilirubinemia requiring phototherapy according to the guidelines of the American Academy of Pediatrics and recommendations for management of premature infants under 35 weeks, adopted by the Kangaroo Mother Care Ambulatory Program.
- Start of jaundice at a chronological age greater than 48 hours.
- Bilirubin level ≤18 mg / dL
- Knowledge of blood groups of mother and child.
- Parents are required to sign informed consent where they agree to participate in the study.
Who cannot join
- Parents without availability to stay in the Kangaroo Mother Care Program for at least 6 hours.
- Extensive skin lesions due to burns or sloughing at the physical examination prior to entering the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effectiveness, Safety and Perceptions With the Use of One LED Blanket Device in the Ambulatory Treatment of Neonatal Jaundice
Objective: to evaluate the effectiveness, safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy to which a LED light mesh has been incorporated(a blanket), comparing it with the Ohmeda BiliBlanket Plus®. Methods: randomized controlled clinical trial with preterm or low birth weight infants requiring phototherapy. The study protocol was evaluated and accepted by the San Ignacio Hospital and "Pontificia Universidad Javeriana" research committee. Informed consent was requested from parents and the authors declared no conflict of interest. Sample size and allocation: using the STATA 12 program, a sample size of 64 patients was calculated(5% losses), 32 for each group, with significance level of 0.05, power of 80% and difference in bilirubin decreasing of at least 0,1 mg/dl/h with standard deviation of 0.14 mg/dl/h. A computer program randomized the allocation to the intervention and the concealment of the assignment was through sealed opaque envelopes. Seric bilirubin levels were taken at the start and at the end of phototherapy. Controls were done every 2 hours with the Bilicheck spectrophotometer device. Axillary temperature was measured at the beginning of phototherapy, at 30 min, 60 min, and every 2 hours during intervention. Physical examination and recording of side effects related were performed. Parents and health personnel answered a survey on comfort and perceptions with the use of the devices at the end of phototherapy. Analysis: Comparison of means was made for the decrease of bilirubin levels and body temperatures and chi-square for incidence of side effects and results of the survey.
Read the detailed description
Background: Jaundice due to hyperbilirubinemia is the most common entity that requires medical management in neonates. About 50% of full-term newborns and 80% of premature infants develop jaundice. The effectiveness of phototherapy for neonatal jaundice depends on two factors: the spectrum of light emitted and the spectral irradiation of light. An ideal phototherapy device should have a broad light emission surface, in order to cover the maximum of the body surface in the horizontal plane, it should be durable, generate relatively little heat and provide a wavelength and light intensity (radiation) optimal (460-490nm and ≥ 30uw / cm2 / nm). The conventional phototherapy devices use fluorescent lamps that emit heat and require eye protectors, in addition to increasing water losses, which requires a permanent monitoring of vital functions and temperature. Its use imposes hospitalization and consequently mother-child separation, always traumatic. The most recent devices use light emitting diodes (LED light) as the light source. Objective: to evaluate the effectiveness, safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy to which a LED light mesh has been incorporated (one blanket), comparing it with the Ohmeda BiliBlanket Plus®, used at the Kangaroo Mother Care Program for intermittent ambulatory phototherapy. Methods: randomized controlled clinical trial with preterm or low birth weight infants that required phototherapy according to the guidelines of the American Academy of Pediatrics. The Protocol was evaluated and accepted by the "Hospital Universitario San Ignacio and Pontificia Universidad Javeriana research committee". Informed consent was requested from parents and the authors declared no conflict of interest. Sample size and allocation: using the STATA 12 program, a sample size of 64 patients was calculated, 32 for each group, with significance level of 0.05, power of 80% and difference in bilirubin decreasing of at least 0,1 mg/dl/h with standard deviation of 0.14 mg/dl/h and 5% of losses. A computer program randomized the allocation to the intervention and the concealment of the assignment was through sealed opaque envelopes. Seric bilirubin levels were taken at the start and at the end of phototherapy. Controls were done every 2 hours with bilicheck spectrophotometer device. Axillary temperature was measured at the beginning of phototherapy, at 30 min, 60 min, and every 2 hours during intervention. Physical examination, recording of side effects related, mortality and requirement of hospital treatment were performed. Parents and health personnel answered a survey on comfort and perceptions with the use of the devices at the end of phototherapy. Analysis: Comparison of means was made for the decrease of bilirubin levels and body temperatures and chi-square for incidence of side effects, hospitalization, mortality and results of the survey.
- Conditions
- Jaundice, Neonatal, Phototherapy
- Being tested
- Neomedlight Phototherapy Blanket, Ohmeda-Fiber Optic Phototherapy Blanket
- Keywords
- infant, newborn, devices, treatment, hyperbilirubinemia
- Medical subject headings
- Jaundice, Neonatal, Hyperbilirubinemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neomedlight Phototherapy BlanketDevice
The NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position.
Ohmeda-Fiber Optic Phototherapy BlanketDevice
This device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm).
| Study group | Role | What they receive |
|---|---|---|
| Neomedlight Phototherapy Blanket | Experimental | Phototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period. Receives: Device: Neomedlight Phototherapy Blanket |
| Ohmeda-Fiber Optic Phototherapy Blanket | Active comparator | Phototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket Receives: Device: Ohmeda-Fiber Optic Phototherapy Blanket |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bilirubin change rate in mg/dl/h
Bilirubin lowering rate (initial seric bilirubin- final seric bilirubin/time of phototherapy).
Measured: through study completion, an average of 6 hours
Secondary outcomes (9)
Patient temperature during phototherapy
Axillary temperatures at 30 min, 60 min, 1 hour, 2 hours, 4 hours and 6 hours of phototherapy.
Measured: through study completion, an average of 6 hours
Incidence of skin lesions related to phototherapy
rash, burns, etc... related to phototherapy
Measured: through study completion, an average of 6 hours
Incidence of dehydration related to phototherapy
Dehydration documented with physical examination and weight
Measured: through study completion, an average of 6 hours
Incidence of diarrhea related to phototherapy
Documented diarrhea
Measured: through study completion, an average of 6 hours
Incidence of other side effects related to phototherapy
Other effects recorded in clinic history related to phototherapy
Measured: through study completion, an average of 6 hours
Perceptions of parents with the use of devices
Comfort with heat, humidity, breastfeeding, proximity and possibility of contact with the baby. The investigators did a validated survey at the end of treatment using a Likert scale(1-7): 1=uncomfortable. 7=comfortable. 4=indifferent
Measured: At study completion, an average of 6 hours.
Perceptions of the health team with the use of the devices
Comfort cleaning and using the device and comfort with light, heat, humidity, and feeding and taking care of the baby. The investigators did a validated survey at the end of treatment using a Likert scale(1-7): 1=uncomfortable. 7=comfortable, 4=indifferent
Measured: At study completion, an average of 6 hours.
Hospitalization for hyperbilirubinemia
Rate of hospitalization for hyperbilirubinemia
Measured: Between beginning of treatment and 72 hours after
Mortality
Rate of mortality related to treatment
Measured: Between beginning of treatment and 72 hours after
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2018
- Study start1 Mar 2016
- Primary completion5 Oct 2017
- Study completion5 Oct 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Jaundice, NeonatalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel assignment randomized controlled clinical trial with preterm or low birth weight infants who have low risk hyperbilirubinemia requiring phototherapy
- Masking
- None (open label)
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nathalie Charpak
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital Universitario San Ignacio
- Responsible party
- Sponsor-investigator, Nathalie Charpak, Kangaroo Foundation
- Investigators
- Nathalie Charpak, Dr., Study director, Kangaroo Foundation Director
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03569254
- Sponsor's protocol ID
- 2015/187
- Acronym
- LEDlightT2
- Status last verified
- Jul 2018
- First submitted
- 4 Jun 2018
- Last updated
- 19 Jul 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness, Safety and Perceptions With the Use of One LED Blanket Device in the Ambulatory Treatment of Neonatal Jaundice
- ClinicalTrials.gov ID
- NCT03569254
- Acronym / sponsor ID
- LEDlightT2 / 2015/187
- Conditions
- Jaundice, Neonatal, Phototherapy
- Keywords
- infant, newborn, devices, treatment, hyperbilirubinemia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Nathalie CharpakUniversity, hospital or other
- Collaborators
- Hospital Universitario San Ignacio
- Study start
- 1 Mar 2016 (actual)
- Primary completion
- 5 Oct 2017 (actual)
- Study completion
- 5 Oct 2017 (actual)
- First posted
- 26 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective: to evaluate the effectiveness, safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy to which a LED light mesh has been incorporated(a blanket), comparing it with the Ohmeda BiliBlanket Plus®. Methods: randomized controlled clinical trial with preterm or low birth weight infants requiring phototherapy. The study protocol was evaluated and accepted by the San Ignacio Hospital and "Pontificia Universidad Javeriana" research committee. Informed consent was requested from parents and the authors declared no conflict of interest. Sample size and allocation: using the STATA 12 program, a sample size of 64 patients was calculated(5% losses), 32 for each group, with significance level of 0.05, power of 80% and difference in bilirubin decreasing of at least 0,1 mg/dl/h with standard deviation of 0.14 mg/dl/h. A computer program randomized the allocation to the intervention and the concealment of the assignment was through sealed opaque envelopes. Seric bilirubin levels were taken at the start and at the end of phototherapy. Controls were done every 2 hours with the Bilicheck spectrophotometer device. Axillary temperature was measured at the beginning of phototherapy, at 30 min, 60 min, and every 2 hours during intervention. Physical examination and recording of side effects related were performed. Parents and health personnel answered a survey on comfort and perceptions with the use of the devices at the end of phototherapy. Analysis: Comparison of means was made for the decrease of bilirubin levels and body temperatures and chi-square for incidence of side effects and results of the survey.
Detailed description
Background: Jaundice due to hyperbilirubinemia is the most common entity that requires medical management in neonates. About 50% of full-term newborns and 80% of premature infants develop jaundice. The effectiveness of phototherapy for neonatal jaundice depends on two factors: the spectrum of light emitted and the spectral irradiation of light. An ideal phototherapy device should have a broad light emission surface, in order to cover the maximum of the body surface in the horizontal plane, it should be durable, generate relatively little heat and provide a wavelength and light intensity (radiation) optimal (460-490nm and ≥ 30uw / cm2 / nm). The conventional phototherapy devices use fluorescent lamps that emit heat and require eye protectors, in addition to increasing water losses, which requires a permanent monitoring of vital functions and temperature. Its use imposes hospitalization and consequently mother-child separation, always traumatic. The most recent devices use light emitting diodes (LED light) as the light source. Objective: to evaluate the effectiveness, safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy to which a LED light mesh has been incorporated (one blanket), comparing it with the Ohmeda BiliBlanket Plus®, used at the Kangaroo Mother Care Program for intermittent ambulatory phototherapy. Methods: randomized controlled clinical trial with preterm or low birth weight infants that required phototherapy according to the guidelines of the American Academy of Pediatrics. The Protocol was evaluated and accepted by the "Hospital Universitario San Ignacio and Pontificia Universidad Javeriana research committee". Informed consent was requested from parents and the authors declared no conflict of interest. Sample size and allocation: using the STATA 12 program, a sample size of 64 patients was calculated, 32 for each group, with significance level of 0.05, power of 80% and difference in bilirubin decreasing of at least 0,1 mg/dl/h with standard deviation of 0.14 mg/dl/h and 5% of losses. A computer program randomized the allocation to the intervention and the concealment of the assignment was through sealed opaque envelopes. Seric bilirubin levels were taken at the start and at the end of phototherapy. Controls were done every 2 hours with bilicheck spectrophotometer device. Axillary temperature was measured at the beginning of phototherapy, at 30 min, 60 min, and every 2 hours during intervention. Physical examination, recording of side effects related, mortality and requirement of hospital treatment were performed. Parents and health personnel answered a survey on comfort and perceptions with the use of the devices at the end of phototherapy. Analysis: Comparison of means was made for the decrease of bilirubin levels and body temperatures and chi-square for incidence of side effects, hospitalization, mortality and results of the survey.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Parallel assignment randomized controlled clinical trial with preterm or low birth weight infants who have low risk hyperbilirubinemia requiring phototherapy
| Arm | Type | Receives |
|---|---|---|
| Neomedlight Phototherapy Blanket | Experimental | Device: Neomedlight Phototherapy BlanketPhototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period. |
| Ohmeda-Fiber Optic Phototherapy Blanket | Active comparator | Device: Ohmeda-Fiber Optic Phototherapy BlanketPhototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket |
Who may qualify
- Ages
- Up to 1 month
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Low Risk Hyperbilirubinemia requiring phototherapy according to the guidelines of the American Academy of Pediatrics and recommendations for management of premature infants under 35 weeks, adopted by the Kangaroo Mother Care Ambulatory Program.
- Start of jaundice at a chronological age greater than 48 hours.
- Bilirubin level ≤18 mg / dL
- Knowledge of blood groups of mother and child.
- Parents are required to sign informed consent where they agree to participate in the study.
Key exclusion criteria (2 listed)
- Parents without availability to stay in the Kangaroo Mother Care Program for at least 6 hours.
- Extensive skin lesions due to burns or sloughing at the physical examination prior to entering the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neomedlight Phototherapy BlanketThe NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position. | Device | Neomedlight Phototherapy Blanket |
| Ohmeda-Fiber Optic Phototherapy BlanketThis device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm). | Device | Ohmeda-Fiber Optic Phototherapy Blanket |
Primary outcome
Bilirubin change rate in mg/dl/h
Time frame: through study completion, an average of 6 hours
Bilirubin lowering rate (initial seric bilirubin- final seric bilirubin/time of phototherapy).
9 secondary outcomes
Patient temperature during phototherapy
Time frame: through study completion, an average of 6 hours
Incidence of skin lesions related to phototherapy
Time frame: through study completion, an average of 6 hours
Incidence of dehydration related to phototherapy
Time frame: through study completion, an average of 6 hours
Incidence of diarrhea related to phototherapy
Time frame: through study completion, an average of 6 hours
Incidence of other side effects related to phototherapy
Time frame: through study completion, an average of 6 hours
Perceptions of parents with the use of devices
Time frame: At study completion, an average of 6 hours.
Perceptions of the health team with the use of the devices
Time frame: At study completion, an average of 6 hours.
Hospitalization for hyperbilirubinemia
Time frame: Between beginning of treatment and 72 hours after
Mortality
Time frame: Between beginning of treatment and 72 hours after
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jul 2018.
- Individual participant dataSharing planned: No
Related trials for Jaundice, Neonatal
Recruiting
Abdominal Massage for Newborn Jaundice
Neonatal Jaundice
Active, not recruiting
Newborn Abdominal Massage to Prevent Hyperbilirubinemia
Newborn Jaundice
Not yet recruiting
Efficacy of Bifidobacterium Animalis Subsp. Lactis in the Treatment of Indirect Hyperbilirubinemia in Term Neonates
Indirect Hyperbilirubinemia
Not yet recruitingPhase 4
Comparison Of Fenofibrate Vs Phenobarbitone As Adjunct To Phototherapy In Reducing Total Serum Bilirubin In Indirect Hyperbilirubinemia In Neonates
Jaundice, Neonatal
Enrolling by invitation
Hat-Type Glasses Intervention in Phototherapy-Related Newborns
Neonatal Hyperbilirubinemia, Neonatal Jaundice
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nathalie Charpak, Dr. study director
Kangaroo Foundation Director
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neomedlight Phototherapy Blanket and Ohmeda-Fiber Optic Phototherapy Blanket in people with Jaundice, Neonatal and Phototherapy, run by Nathalie Charpak at 1 site in Colombia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bilirubin change rate in mg/dl/h (time frame: through study completion, an average of 6 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2018.